Krystal Biotech, Inc. (KRYS)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Krystal Biotech, Inc. keeps $50 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 16
in 89 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Krystal Biotech topped consensus on both the top and bottom line in the third fiscal quarter of 2026, reported November 2, 2026, with EPS of $2.05 topping the $1.79 estimate (+14.5%) as revenue of $127.3 million topped the $125.8 million consensus (+1.2%). Revenue rose ~30% to about $127.3 million (up from roughly $97.8 million a year ago), reflecting continued commercial momentum around its gene-therapy franchise, while EPS fell ~23% from $2.66 a year ago despite the beat versus expectations. Profitability remained high, with gross margin near 94% on roughly $119.8 million of gross profit and operating margin around 56% alongside about $71.1 million of operating income. Net income declined ~21% year over year to about $63.1 million (down from roughly $79.4 million), even as the company generated operating cash flow of about $91.2 million. For the next period, consensus calls for EPS of $1.91 on revenue of $133.4 million.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. is a NASDAQ-listed biotechnology company developing redosable gene therapies in the United States, with a focus on severe orphan diseases. The company generated $389.1 million in FY2025 revenue and centers its programs on genetic medicines for dermatology and other serious conditions.
Today's Snapshot
KRYS closed 5.6% above yesterday's close, outperforming a weaker sector.
Trading Volume
Above 10d avg 220.6K
286.3K
vs S&P 500 Today
Strong Outperformance
+5.88%
Updated: November 18, 2026 at 21:19 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$303.45 - $322.76Buy
- RSI (14)51.35Neutral
- Stochastic %K (14, 3, 3)43.98Neutral
- MACD Level (12, 26)-5.72Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.